Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydrofolic acid is a reduced derivative of folic acid (vitamin B9), serving as an intermediate in the biosynthesis of tetrahydrofolic acid via the enzyme dihydrofolate reductase. Tetrahydrofolate is essential for the synthesis of purines and pyrimidines—the building blocks of DNA and RNA—making dihydrofolic acid crucial for cell division and growth. Inhibition of its reduction to tetrahydrofolate by drugs such as methotrexate or trimethoprim disrupts nucleic acid synthesis in rapidly dividing cells or bacteria[1][3][5][7]. Dihydrofolic acid itself is not used therapeutically but is widely utilized in biochemical research to study folate metabolism and drug mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydrofolic acid.